LUMENT FINANCE TRUST, INC. (LFT) earnings per share

Next earnings report (estimated)
2026-08-06
Pending company confirmation.
Consensus EPS
$0.03
1 analyst · Range $0.03 – $0.03
Annual history
Fiscal years 2013 – 2025
USD / SHARE 8 PERIODS
Period End Diluted Filed
FY 2025 2025-12-31 -$0.14 2026-03-23
FY 2024 2024-12-31 $0.34 2025-03-19
FY 2023 2023-12-31 $0.29 2024-03-15
FY 2022 2022-12-31 $0.11 2023-03-23
FY 2021 2021-12-31 $0.30 2022-03-15
FY 2020 2020-12-31 $0.34 2021-03-15
FY 2013 2013-12-31 -$1.12 2014-03-12
FY 2013 2012-12-31 $0.00 2014-03-12
Quarterly history
Fiscal years 2014 – 2026
USD / SHARE 24 PERIODS
Period End Diluted Filed
Q1 2026 2026-03-31 -$0.02 2026-05-15
Q4 2025 2025-12-31 -$0.17 2026-03-23
Q3 2025 2025-09-30 $0.01 2025-11-12
Q2 2025 2025-06-30 $0.05 2025-08-08
Q1 2025 2025-03-31 -$0.03 2025-05-12
Q4 2024 2024-12-31 $0.07 2025-03-19
Q3 2024 2024-09-30 $0.10 2024-11-12
Q2 2024 2024-06-30 $0.07 2024-08-12
Q1 2024 2024-03-31 $0.11 2024-05-09
Q4 2023 2023-12-31 $0.08 2024-03-15
Q3 2023 2023-09-30 $0.10 2023-11-13
Q2 2023 2023-06-30 $0.03 2023-08-08
Q1 2023 2023-03-31 $0.09 2023-05-11
Q4 2022 2022-12-31 $0.02 2023-03-23
Q3 2022 2022-09-30 $0.01 2022-11-08
Q2 2022 2022-06-30 $0.04 2022-08-08
Q1 2022 2022-03-31 $0.05 2022-05-09
Q4 2021 2021-12-31 $0.10 2022-03-15
Q3 2021 2021-09-30 $0.05 2021-11-09
Q2 2021 2021-06-30 $0.04 2021-08-09
Q1 2021 2021-03-31 $0.11 2021-05-11
Q4 2020 2020-12-31 $0.10 2021-03-15
Q3 2020 2020-09-30 $0.10 2020-11-06
Q1 2014 2014-03-31 2014-05-09

Methodology

Annual rows come from the filer's 10-K and Q1–Q3 rows from the matching 10-Q; Q4 is derived as full-year minus nine-month YTD because XBRL doesn't tag Q4 as its own period. EPS Basic and EPS Diluted are reported directly by the filer.

For the exact XBRL concepts and formulas, see the methodology reference for EPS, FCF per share, the Q4 derivation, and split adjustment.

LFT CIK 0001547546 Source: EDGAR filings · all facts

Related tickers

SOTK

SONO TEK CORP

CBL

CBL & ASSOCIATES PROPERTIES, INC.

KPTI

Karyopharm Therapeutics Inc.